Category: Our News

CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable, a biotechnology company founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is a Canadian start-up emerging as a market leader in finding orally-bioavailable molecules. Today, the company announced $840,000 in funding from…

Philadelphia, June 16, 2015. – CQDM and Ontario Centres of Excellence(OCE) will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM’s 2014 Explore…

Vancouver, May 26, 2015. – CQDM, Brain Canada and the Ontario Brain Institute (OBI) award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind…

Montreal, April 15th, 2015 – The Chairman of the Board, Dr. Léon Gosselin, and the President and CEO of CQDM, Dr. Diane Gosselin, are pleased to announce the appointment of Dr. Michel Goldman, former Executive Director at the Innovative Medicines Initiative (IMI), as member of CQDM’s Board of Directors. Michel Goldman led the IMI from 2009 to 2014…

CQDM supports precompetitive research whose technological breakthroughs will boost the productivity of biopharmaceutical R&D and provide solutions to the unmet critical needs of the industry. Although CQDM members share costs, risks and research results, the intellectual property resulting from the CQDM-funded research will belong to the researchers and their respective institutions. A non-exclusive license option will…

Montreal, January 19, 2015. – CQDM is very pleased to announce that Janssen Inc. (Janssen) is joining its public-private consortium to support highly innovative, collaborative research in Canada to accelerate drug discovery and development, in order to bring better treatments to patients. The new partnership with Janssen brings to nine (9) the number of pharmaceutical companies around…

Montreal, January 7th, 2015 – CQDM is pleased to announce the publication of its 2014 Activity Report. Proud of the progress made in the last year, 2014 was the year of partnerships. In addition to welcoming Sanofi Canada into its consortium, CQDM extended its collaborations throughout Canada and globally. CQDM now has an outstanding portfolio of 35 projects carried out by…

Montreal, December 16th, 2014 – The Chairman of the Board, Mr. Léon Gosselin and the President and CEO of CQDM, Ms. Diane Gosselin are pleased to announce the appointment of Ms. Louise Proulx, Chief Development Officer at Therillia as a new member of CQDM’s Board of Directors, of Professor Hans Christian Fibiger, Associate Dean research at the Faculty of Medicine of…

Montreal, November 20th, 2014 – CQDM, Alsace BioValley and Lyonbiopôle launch the 5th competition of the Quebec/France Program to accelerate the discovery and development of new drugs. Once again this year, the goal of the joint program is to strengthen biomedical research in Quebec, Alsace and Rhône-Alpes by aligning scientific resources and expertise. More specifically, it is…

Michel Grenier, Executive Director, Centre d’entrepreneuriat, ESG UQAM, Mélissa Denis, Director, National and Sector Sales, Business Solutions, TC Media, Pierre Miron, Senior Vice-President, Operations and Information Technology, Caisse de dépôt et placement du Québec, Kathleen Zicat, Senior Vice-President, Particulier Québec, National Bank of Canada, Lise Bissonnette, Chair of the Board, UQAM, Robert Proulx, Rector, UQAM,…